The high local failure rate in @entity1 with locally advanced @entity189 treated with standard radiation has spurred interest in radiosensitization. @entity900 is the most active single chemotherapeutic agent in squamous @entity189 , and is considered to be a radiosensitizer. Based on a previous single-institution study looking at continuous low-dose intra-arterial @entity900 given throughout planned radiation therapy in @entity1 with advanced @entity189 , the Gynecologic Oncology Group initiated a limited access pilot study to assess the feasibility of this treatment method for a group-wide study. @entity1 with locally advanced squamous @entity189 and surgically documented negative periaortic lymph nodes were eligible for the study. During surgical staging, the catheters of a totally implantable pump were placed in the internal iliac arteries. The pump was filled with @entity900 which was delivered at 4.5-6.5 mg day-1 continuously throughout both external radiation and brachytherapy. Drug distribution through the catheters was determined using radiolabelled macro-aggregated albumin particles. Three of nine evaluable @entity1 were free of disease at follow-up. Drug distribution was less than optimal through 4.6% of the pump catheters. Five @entity1 had premature discontinuation of the @entity900 for various reasons. These problems resulted in low accrual and subsequent closure of the study. This treatment method is not feasible for a phase III evaluation on a group-wide basis.

Continuous intra-arterial XXXX combined with radiotherapy in locally advanced squamous @entity189 : a Gynecologic Oncology Group pilot study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma of the cervix']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
